Pain Therapeutics (PTIE) 2.32 $PTIE
Global Neuropathic Pain Therapeutics Pipeline Review H1 2016 - 121 Companies & Drug Profiles - Research and Markets
BusinessWire - Mon Aug 29, 11:36AM CDT
Research and Markets has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
Global Pain Therapeutics Report 2016 - Focus on Latest Drugs, Markets and Companies - Research and Markets
PR Newswire Europe - Fri May 27, 7:10AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/thf6d3/pain_therapeutics] to their offering.
PTIE: 2.32 (-0.07)
Global Pain Therapeutics Report 2016-2025 - Drugs, Markets and Companies Forecasts
GlobeNewswire - Fri May 27, 3:17AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.32 (-0.07)
Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets
BusinessWire - Thu May 26, 8:36AM CDT
Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY(R)
GlobeNewswire - Thu May 19, 8:00AM CDT
- August 5 is FDA's Tentative Date for Advisory Committee Meeting -
PTIE: 2.32 (-0.07)
Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting
GlobeNewswire - Wed May 11, 8:05AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX.
PTIE: 2.32 (-0.07)
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Reports Q1 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share.
PTIE: 2.32 (-0.07)
Global Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets
BusinessWire - Thu Apr 28, 1:06PM CDT
Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016
GlobeNewswire - Tue Apr 12, 3:05PM CDT
- Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT -
PTIE: 2.32 (-0.07)
Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets
BusinessWire - Wed Mar 30, 1:54PM CDT
Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim
BusinessWire - Wed Mar 30, 6:00AM CDT
--Acquisition Creates One of the Largest Exclusively Pain-Focused, Non-Opioid Pipelines in Active Development
PTIE: 2.32 (-0.07)
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) announced today that it has resubmitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for REMOXY(R), an abuse-deterrent formulation of extended-release oxycodone (CII) capsules. Pain Therapeutics expects to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review designation.
PTIE: 2.32 (-0.07)
Global Pain Therapeutics, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:39AM CST
'PAIN THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the PAIN THERAPEUTICS, INC.'s pharmaceutical research and development focus.
PTIE: 2.32 (-0.07)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.45 (+0.01), PFE: 34.68 (-0.12), AMGN: 170.13 (+0.07), ZYNE: 8.57 (+0.09), NKTR: 18.11 (+0.26), AZN: 32.60 (-0.21), VBAY: (), PTIE: 2.32 (-0.07)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.45 (+0.01), COLL: 8.83 (+0.50), LLY: 77.23 (-0.52), AGN: 237.76 (+3.22), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), EGLT: 6.61 (-0.25), ACAD: 32.10 (-0.03), CLCD: 10.25 (-0.02), HRTX: 18.33 (-0.27), AZN: 32.60 (-0.21), ABBV: 64.03 (-0.07), PTIE: 2.32 (-0.07)
Global Moderate Pain Development Pipeline Insights Report 2016
M2 - Mon Feb 01, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcjhtj/moderate) has announced the addition of the "Moderate Pain-Pipeline Insights, 2016" report to their offering. Moderate Pain-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Moderate Pain. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Moderate Pain. The report also assesses the Moderate Pain therapeutics by Monotherapy, Combination products, molecule type and Route of Administration. Scope - The report provides competitive pipeline landscape of Moderate Pain - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Moderate Pain pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Moderate Pain and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Moderate Pain Overview - Moderate Pain Pipeline Therapeutics - Moderate Pain Therapeutics under Development by Companies - Moderate Pain Filed and Phase III Products - Comparative Analysis - Moderate Pain Phase II Products - Moderate Pain Phase I and IND Filed Products - Moderate Pain Discovery and Pre-Clinical Stage Products - Moderate Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Moderate Pain - Discontinued Products - Moderate Pain - Dormant Products - Companies Involved in Therapeutics Development for Moderate Pain For more information visit http://www.researchandmarkets.com/research/zcjhtj/moderate
PTIE: 2.32 (-0.07)
Global Neuropathic Pain Therapeutics Pipeline Review H1 2016 - 121 Companies & Drug Profiles - Research and Markets
BusinessWire - Mon Aug 29, 11:36AM CDT
Research and Markets has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
Global Pain Therapeutics Report 2016 - Focus on Latest Drugs, Markets and Companies - Research and Markets
PR Newswire Europe - Fri May 27, 7:10AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/thf6d3/pain_therapeutics] to their offering.
PTIE: 2.32 (-0.07)
Global Pain Therapeutics Report 2016-2025 - Drugs, Markets and Companies Forecasts
GlobeNewswire - Fri May 27, 3:17AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.32 (-0.07)
Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets
BusinessWire - Thu May 26, 8:36AM CDT
Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY(R)
GlobeNewswire - Thu May 19, 8:00AM CDT
- August 5 is FDA's Tentative Date for Advisory Committee Meeting -
PTIE: 2.32 (-0.07)
Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting
GlobeNewswire - Wed May 11, 8:05AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX. PTIE: 2.32 (-0.07)
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Reports Q1 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share. PTIE: 2.32 (-0.07)
Global Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets
BusinessWire - Thu Apr 28, 1:06PM CDT
Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016
GlobeNewswire - Tue Apr 12, 3:05PM CDT
- Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT -
PTIE: 2.32 (-0.07)
Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets
BusinessWire - Wed Mar 30, 1:54PM CDT
Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.32 (-0.07)
Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim
BusinessWire - Wed Mar 30, 6:00AM CDT
--Acquisition Creates One of the Largest Exclusively Pain-Focused, Non-Opioid Pipelines in Active Development
PTIE: 2.32 (-0.07)
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.61 (-0.06), PTIE: 2.32 (-0.07)
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) announced today that it has resubmitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for REMOXY(R), an abuse-deterrent formulation of extended-release oxycodone (CII) capsules. Pain Therapeutics expects to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review designation. PTIE: 2.32 (-0.07)
Global Pain Therapeutics, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:39AM CST
'PAIN THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the PAIN THERAPEUTICS, INC.'s pharmaceutical research and development focus.
PTIE: 2.32 (-0.07)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.45 (+0.01), PFE: 34.68 (-0.12), AMGN: 170.13 (+0.07), ZYNE: 8.57 (+0.09), NKTR: 18.11 (+0.26), AZN: 32.60 (-0.21), VBAY: (), PTIE: 2.32 (-0.07)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.45 (+0.01), COLL: 8.83 (+0.50), LLY: 77.23 (-0.52), AGN: 237.76 (+3.22), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), EGLT: 6.61 (-0.25), ACAD: 32.10 (-0.03), CLCD: 10.25 (-0.02), HRTX: 18.33 (-0.27), AZN: 32.60 (-0.21), ABBV: 64.03 (-0.07), PTIE: 2.32 (-0.07)
Global Moderate Pain Development Pipeline Insights Report 2016
M2 - Mon Feb 01, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcjhtj/moderate) has announced the addition of the "Moderate Pain-Pipeline Insights, 2016" report to their offering. Moderate Pain-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Moderate Pain. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Moderate Pain. The report also assesses the Moderate Pain therapeutics by Monotherapy, Combination products, molecule type and Route of Administration. Scope - The report provides competitive pipeline landscape of Moderate Pain - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Moderate Pain pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Moderate Pain and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Moderate Pain Overview - Moderate Pain Pipeline Therapeutics - Moderate Pain Therapeutics under Development by Companies - Moderate Pain Filed and Phase III Products - Comparative Analysis - Moderate Pain Phase II Products - Moderate Pain Phase I and IND Filed Products - Moderate Pain Discovery and Pre-Clinical Stage Products - Moderate Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Moderate Pain - Discontinued Products - Moderate Pain - Dormant Products - Companies Involved in Therapeutics Development for Moderate Pain For more information visit http://www.researchandmarkets.com/research/zcjhtj/moderate
PTIE: 2.32 (-0.07)
